← Eichor
Study identifier: NCT06561074 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Condition: T-cell Acute Lymphoblastic Leukemia · T-Cell Lymphoblastic Lymphoma  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 2
Planned participants22
Who can joinAll sexes, 1 Month to 21 Years
Healthy volunteersNo

About this study

To learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.

This description comes directly from the study's public registry record.

Talk to the study team

David McCall, MD  ·  (713) 792-6604  ·  dmccall1@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06561074